Hypericum in depressive disorder: a critical review
DOI:
https://doi.org/10.32385/rpmgf.v37i5.12962Keywords:
Hypericum, Depressive disorderAbstract
Objectives: Review the evidence regarding the effectiveness, tolerability, and safety of hypericum in the treatment of depressive disorder (DD).
Data sources: NICE, Canadian Medical Association Infobase, PubMed – Clinical Queries, The Cochrane Library, BMJ, Bandolier, and DARE – Centre for Reviews and Dissemination.
Methods: The research for scientific articles was performed on online Evidence-Based Medicine platforms, with the keywords ‘Hypericum’ and ‘Depressive Disorder’. Articles were selected based on title, year of publication, and abstract.
Results: Two clinical guidelines (CG), three meta-analyses (MA), two systematic reviews (SR), and one original article (OA) were included in this review. One CG reported that hypericum can be used as first-line in mild to moderate major DD and as an adjunct treatment of second-line in moderate to severe major DD. Another CG does not support the use. All of MA and SR conclude that hypericum is more effective than placebo in the treatment of DD, with two MA and two SR added that there is no increase of adverse effects. Two SR mentioned the risk of interactions with other drugs. The OA also affirms the effectiveness of hypericum in postmenopausal women.
Conclusion: There is evidence regarding the efficacy of hypericum in mild to moderate DD. The available data appears to be consistent with its good tolerability, but also in terms of the risk of interactions with other drugs. The limitations of the recommendation are essentially due to the mechanisms of action that are not fully understood.
Downloads
References
Apaydin EA, Maher AR, Shanman R, Booth MS, Miles JN, Sorbero ME, et al. A systematic review of St. John’s wort for major depressive disorder. Syst Rev. 2016;5(1):148.
Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2015;13(1):69-79.
Direção-Geral da Saúde. Portugal, Saúde mental em números – 2014. Lisboa: DGS; 2014.
Kasper S. Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. Wien Med Wochenschr. 2015;165(11-12):217-28.
Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol. 1999;12(1):7-10.
Canedo F, Gamboa A. Hipericão: interacções medicamentosas. Bol Farmacovigilância. 2000;4(1):3-4.
Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol. 1998;54(8):589-94.
Observatório de Interações Planta-Medicamento. Erva de S. João / Hipericão (Hypericum perforatum) [homepage]. Coimbra: Universidade de Coimbra; 2021. Available from: http://www.oipm.uc.pt/interacoes/index.php?target=list&search=plantas&start_at=20
Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and alternative medicine treatments. Can J Psychiatry. 2016;61(9):576-87.
Scottish Intercollegiate Guidelines Network. Non-pharmaceutical management of depression in adults: a national clinical guideline [Internet]. Edinburgh: SIGN; 2010. Available from: https://www.ashlandmhrb.org/upload/non-pharmaceutical_management_of_depression_in_adults_-_nhs_-_a_national_clinical_guideline.pdf
Sarris J. Herbal medicines in the treatment of psychiatric disorders: 10‐year updated review. Phytother Res. 2018;32(7):1147-62.
Cipriani A, Barbui C, Butler R, Hatcher S, Geddes J. Depression in adults: drug and physical treatments. BMJ Clin Evid. 2011;2011:1003.
Eatemadnia A, Ansari S, Abedi P, Najar S. The effect of Hypericum perforatum on postmenopausal symptoms and depression: a randomized controlled trial. Complement Ther Med. 2019;45:109-13.
INFARMED. Plantas medicinais: interações medicamentosas. Bol Farmacovigilância. 2020;24(3):5-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
